Interestingly, although the anti-CCP2 mean ratio at baseline in the RA cohort was up to 3.5-fold higher than that observed in the non-RA group (P < 0.0001), the percentage of patients with either low or high anti-CCP2 titers at enrollment did not differ in the RA and non-RA groups. Here, AGBL2 is linked to rheumatoid arthritis.